HeyJaredRyner Lai
- Indexed articles, last 90 days
- 9
- Latest publication
- Sep 17, 2026
- Outlet visibility, for Oncology Nurse Advisor
- Top 5M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Allo-HSCT Effective, Potentially Curative for Hepatosplenic T-Cell Lymphoma (opens the original)
Read excerpt
Allogeneic stem cell transplantation (allo-HSCT) is effective and potentially curative among patients with hepatosplenic T-cell lymphoma, while autologous stem cell transplantation (auto-HSCT) is recommended only for patients ineligible for allo-HSCT who achieve a complete response because of the significant risk of relapse, according to a study published in The Lancet Haematology. Standards of care for hepatosplenic T-cell lymphoma include therapies such as cyclophosphamide, doxorubicin, vincri
Allo-HSCT Effective, Potentially Curative for Hepatosplenic T-Cell Lymphoma - Oncology Nurse Advisor (opens the original)
Read excerpt
Allogeneic stem cell transplantation (allo-HSCT) is effective and potentially curative among patients with hepatosplenic T-cell lymphoma, while autologous stem cell transplantation (auto-HSCT) is recommended only for patients ineligible for allo-HSCT who achieve a complete response because of the significant risk of relapse, according to a study published in The Lancet Haematology. Standards of care for hepatosplenic T-cell lymphoma include therapies such as cyclophosphamide, doxorubicin, vincri
Oral Sonrotoclax Shows Rapid, Durable Responses in Heavily Pretreated R/R MCL (opens the original)
Read excerpt
Oral sonrotoclax was associated with rapid and durable responses among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who were heavily pretreated, according to a study published in Hematologic Malignancy. Sonrotoclax is a next-generation B-cell lymphoma 2 (BCL2) inhibitor that is more selective and potent than venetoclax, which is sometimes used off-label in R/R MCL. In addition, it has a shorter half-life, with no drug accumulation in humans. Researchers presented the findin
Ramelteon Ineffective for Postoperative Delirium in Older Cancer Patients - Oncology Nurse Advisor (opens the original)
Read excerpt
Results of a phase III study, ramelteon was not associated with a reduction in postoperative delirium in older adults undergoing major cancer surgery, according to a presentation at the 2026 ASCO Annual Meeting. A common complication after major cancer surgery among older adults is delirium, which can be severe. At present, the American Psychiatric Association does not recommend pharmacologic intervention due to insufficient high-quality evidence. Ramelteon is a melatonin receptor agonist. It ha
Outpatient Monitoring of CAR T-Cell Therapy Reduces Hospitalization, With No Impact on Mortality - Oncology Nurse Advisor (opens the original)
Read excerpt
Outpatient monitoring of patients with hematologic malignancies undergoing chimeric antigen receptor (CAR) T-cell therapy was associated with less healthcare resource utilization without a significant change in patient mortality. These findings were presented at the 2026 ASCO Annual Meeting. CAR T-cell therapy has revolutionized the treatment of hematologic malignancies. Traditionally, postinfusion monitoring is carried out in the inpatient setting. However, to save costs and time, outpatient mo
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Oncology Nurse Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.